NCT05262335 (ALTER-G-001) is a Phase 2 clinical trial of Anlotinib + Oxaliplatin + Capecitabine in Gastrointestinal Tumors, sponsored by Ruijin Hospital.

Who is sponsoring NCT05262335?

NCT05262335 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT05262335?

Interventions in NCT05262335: Anlotinib + Oxaliplatin + Capecitabine, Anlotinib + Cisplatin + Paclitaxel/ Docetaxel, Anlotinib + Standard first-line chemotherapy.

What condition does NCT05262335 study?

NCT05262335 studies Gastrointestinal Tumors.

Is NCT05262335 still recruiting?

NCT05262335 is currently status unknown. Last updated 28 November 2023.

Last reviewed 2023-11-28 · How we verify

NCT05262335: ALTER-G-001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)

Status unknown Phase 2 Last updated 28 November 2023

What this trial tests

Phase 2 trial testing Anlotinib + Oxaliplatin + Capecitabine in Gastrointestinal Tumors in 116 participants. Status unknown.

Timeline

1 December 2021

Primary endpoint
1 December 2023

1 December 2024

Quick facts

Lead sponsor	Ruijin Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	116
Start date	1 December 2021
Primary completion	1 December 2023
Estimated completion	1 December 2024
Sites	7 locations across China

Drugs / interventions tested

Anlotinib + Oxaliplatin + Capecitabine — full drug profile →
Anlotinib + Cisplatin + Paclitaxel/ Docetaxel — full drug profile →
Anlotinib + Standard first-line chemotherapy — full drug profile →

Conditions studied

Gastrointestinal Tumors — all drugs for Gastrointestinal Tumors →

Sponsor

Ruijin Hospital

Who can join

Adults 18 to 75, any sex, with Gastrointestinal Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open, multi-cohort, multi-center, exploratory and phase II clinical trial. To evaluate the efficacy and safety Anlotinib combined with chemotherapy as first-line and maintenance therapy for Gastrointestinal Tumors with Unresectable Liver Metastases.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib.
Li H, Feng H, Zhang T, Wu J, et al · · 2024 · cited 19× · PMID 38515149 · DOI 10.1186/s12943-024-01971-7
CircRNAs in colorectal cancer: potential roles, clinical applications, and natural product-based regulation.
Yang J, Fan Q, Wang Y, Liu Y, et al · · 2025 · cited 5× · PMID 39944836 · DOI 10.3389/fonc.2025.1525779
Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial.
Wu JW, Zhou CF, Han ZX, Zhang H, et al · · 2024 · cited 1× · PMID 39648217 · DOI 10.1038/s41392-024-02051-4

Verify or expand the search:

Other recruiting trials for Gastrointestinal Tumors

Currently open trials in the same condition.

NCT07067385 — Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment · Phase 1 · recruiting
NCT06775080 — The Use of Propranolol in the Perioperative Period of Resectable Gastrointestinal Tumors · Phase 2 · recruiting
NCT07104877 — A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tu · NA · active not recruiting
NCT06152757 — BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors · EARLY_PHASE1 · recruiting
NCT06478030 — Combined Screening for Gastrointestinal Tumors · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05262335 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 28 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05262335.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing